Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4362
Name cervical cancer
Definition A female reproductive organ cancer that is located_in the cervix.
Source DiseaseOntology.org
Alt Ids DOID:4361
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA E545K PW12 cervical cancer sensitive detail...
PIK3CA mutant Cetuximab cervical cancer decreased response detail...
RB1 mut TP53 mut R547 cervical cancer sensitive detail...
PIK3CA mutant Alpelisib cervical cancer predicted - sensitive detail...
NTRK1 fusion Larotrectinib cervical cancer sensitive detail...
NTRK2 fusion Larotrectinib cervical cancer sensitive detail...
NTRK1 fusion Entrectinib cervical cancer sensitive detail...
NTRK2 fusion Entrectinib cervical cancer sensitive detail...
PIK3CA mutant Perifosine cervical cancer not predictive detail...
PIK3CA mutant WX390 cervical cancer predicted - sensitive detail...
PIK3CA E545K Alpelisib cervical cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00292955 Phase II Cetuximab Cisplatin Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Unknown status USA 0
NCT00980954 Phase III Carboplatin + Paclitaxel Cisplatin Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Active, not recruiting USA | CAN 2
NCT01711515 Phase I Ipilimumab Cisplatin Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer Completed USA 0
NCT01958112 Phase II Trametinib + Uprosertib GSK1120212+GSK2141795 for Cervical Cancer Terminated USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA 2
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 8
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated USA 1
NCT02312804 Phase I Paclitaxel Carboplatin Infigratinib Ph Ib/BGJ398/Cervix and Other Solid Tumors Withdrawn 0
NCT02405221 Phase I TA-CIN Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer Active, not recruiting USA 0
NCT02426892 Phase II Nivolumab Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors Completed USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Active, not recruiting USA | FRA | ESP | DEU | BEL 6
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting USA | ITA | ESP 2
NCT02635360 Phase II Cisplatin Pembrolizumab Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer Active, not recruiting USA 0
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Completed USA 0
NCT02812056 Phase I Alisertib + Sapanisertib Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn 0
NCT02865135 Phase Ib/II Cyclophosphamide + DPX-E7 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Active, not recruiting USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03104699 Phase Ib/II Balstilimab Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer Active, not recruiting USA | FRA | ESP | BEL 5
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | FRA | DEU | CAN 5
NCT03257267 Phase III Irinotecan Gemcitabine Vinorelbine Pemetrexed Disodium Cemiplimab Topotecan Study of REGN2810 in Adults With Cervical Cancer Active, not recruiting USA | ITA | ESP | CAN | BEL 9
NCT03260023 Phase Ib/II Avelumab Avelumab + Tipapkinogene sovacivec Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers Recruiting USA | FRA | ESP 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting USA 0
NCT03427411 Phase II M7824 Phase II Trial of M7824 in Subjects With HPV Positive Malignancies Active, not recruiting USA 0
NCT03439085 Phase II Durvalumab + MEDI0457 Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers Active, not recruiting USA 0
NCT03452332 Phase I Durvalumab + Tremelimumab Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer Active, not recruiting USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Active, not recruiting USA 1
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Active, not recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Active, not recruiting USA 0
NCT03518606 Phase Ib/II Durvalumab + Tremelimumab + Vinorelbine Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) Active, not recruiting FRA 0
NCT03527264 Phase II Cisplatin + Nivolumab BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer Terminated USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03614949 Phase II Atezolizumab SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer Recruiting USA 0
NCT03618953 Phase I Ad-E6E7 + Atezolizumab + MG1-E6E7 This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher) Active, not recruiting USA | CAN 0
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Recruiting USA | BEL 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA 5
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting USA | ITA 2
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting USA | ITA | ESP 4
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL 2
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Recruiting USA 0
NCT04068753 Phase II Dostarlimab-gxly + Niraparib Niraparib in Combination With TSR-042 in Patients With Recurrent or Progressive Cervix Cancer (STAR) Recruiting USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04122625 Phase Ib/II Nivolumab + Xevinapant Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Completed USA | FRA | ESP 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | FRA | ESP | DEU | BEL 1
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA | ESP 2
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting 2
NCT04287868 Phase Ib/II M7824 + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | FRA | ESP 2
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Active, not recruiting USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP 0
NCT04432597 Phase Ib/II PRGN-2009 M7824 + PRGN-2009 HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers Recruiting USA 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting USA | FRA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Recruiting 3
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Active, not recruiting USA | ITA | ESP | CAN | BEL 10
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Recruiting USA 0
NCT04493619 Phase Ib/II Carboplatin + PLX2853 PLX2853 PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Terminated USA | CAN 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Recruiting USA | FRA | ESP | CAN 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN 1
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04708470 Phase Ib/II Entinostat + M7824 + NHS-IL12 Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04762225 Phase I RPTR-168 RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma Recruiting USA 0
NCT04772989 Phase I AB308 + Zimberelimab A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies Recruiting USA 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04865887 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Advanced Cervical Cancer Recruiting USA 0
NCT04895709 Phase Ib/II BMS-986340 BMS-986340 + Nivolumab A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors Recruiting USA | ITA | ESP | DEU | CAN 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Recruiting 1
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting 1
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Recruiting USA 0
NCT05082259 Phase I ASTX-660 + Pembrolizumab ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) Recruiting 1
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Recruiting FRA 1
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting 1
NCT05132803 Phase I TA-CIN TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers Not yet recruiting USA 0
NCT05216432 Phase I RLY-2608 Fulvestrant + RLY-2608 First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer Recruiting USA 0
NCT05229900 Phase I SGN-ALPV A Study of SGN-ALPV in Advanced Solid Tumors Recruiting USA 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study Recruiting USA 0
NCT05306444 Phase I HBM7008 HBM7008 -Study on Subjects With Advanced Solid Tumors Recruiting 1
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA 0